In the past year, China has rapidly emerged as a key strategic consideration for sponsors planning to run global studies. That marks a sharp shift from the traditional biotech and pharma regional focus, where APAC was often treated as secondary to the US and Europe and brought into development plans only later if timelines, funding, or commercial priorities allowed. That approach is changing rapidly. Across the industry, sponsors are recognising that APAC is no longer simply an optional expansion geography.